Top Mesothelioma Centers in Massachusetts

The top Massachusetts mesothelioma cancer centers include multidisciplinary care facilities, university hospitals and research institutes that offer innovative treatments and open clinical trials. Regional cancer centers such as the Massachusetts General Brigham Cancer Institute give people with mesothelioma access to groundbreaking procedures, including CAR T-cell therapy and proton beam therapy for targeted treatment.

The Dana-Farber Cancer Institute/Harvard Cancer Center is home to some of the best mesothelioma doctors in Boston. Part of the Harvard Medical School system, this exceptional research hospital meets the National Cancer Institute’s highest standards for patient care, clinical trials, support services and mesothelioma treatment in Massachusetts. Dana-Farber is one of the state’s only NCI-Designated comprehensive cancer centers, and its researchers have helped develop nearly half of all modern cancer medications.

Locations of the Top Cancer Centers in Massachusetts

Most of the top cancer centers for mesothelioma treatment in Massachusetts are in or near Boston. Among those are two National Cancer Institute NCI-Designated comprehensive cancer centers. One is the DF/HCC in Boston, and the other is the David H. Koch Institute for Integrative Cancer Research at MIT, often called “The Koch Institute,” in Cambridge. The Brigham Cancer Institute, Boston University Cancer Center and Tufts Medical Center are all within 5 miles.

Some highly rated organizations have secondary cancer care centers in other regions of Massachusetts, potentially making it easier for people with mesothelioma to receive chemotherapy and radiation treatments, post-operative care and recovery support. The Mass General Brigham Cancer Institute network includes oncology centers in Concord, Salem, Nantucket and Northampton.

All Centers (5)

Top Doctors in Massachusetts

The best mesothelioma doctors in Massachusetts are specialists in thoracic surgery, pleural and peritoneal mesothelioma and immunotherapy. With a multidisciplinary care team, people in treatment benefit from personalized plans that target cancer cells precisely, often including chemotherapy, radiation therapy and minimally invasive surgery techniques. At Brigham and Women’s Hospital in Boston, pleural mesothelioma experts Dr. Scott Swanson and Dr. Hassan Khalil specialize in Video-Assisted Thoracic Surgery and robotic surgery.

Dr. Martin Goodman at Tufts Medical Center is one of the best peritoneal mesothelioma doctors in Massachusetts, with more than a decade of expertise in cytoreductive surgery and heated chemotherapy. At the Dana-Farber Cancer Institute, Dr. Pasi Jänne helps patients with pleural mesothelioma by using cutting-edge immunotherapy and heated chemotherapy.

Dr. Elizabeth Baldini

Elizabeth Baldini

Pleural Specialist | Thoracic Radiology

Expertise:
Thoracic Malignancies Clinical Research
Brigham and Women’s Hospital • Boston, Massachusetts
View Profile
Expertise:
Thoracic Malignancies Clinical Research
Brigham and Women’s Hospital
Boston, Massachusetts
View Profile

Dr. Elizabeth Baldini focuses on clinical research and the treatment of mesothelioma, and she has authored papers with pioneer Dr. David Sugarbaker.

Read Bio
Dr. Laurence H. Brinckerhoff

Laurence H. Brinckerhoff

Pleural Specialist | Thoracic Surgery

Expertise:
Minimally Invasive Surgery Clinical Trials
Tufts Medical Center • Boston, Massachusetts
View Profile
Expertise:
Minimally Invasive Surgery Clinical Trials
Tufts Medical Center
Boston, Massachusetts
View Profile

Dr. Laurence Brinckerhoff is chief of thoracic surgery and leader of the Interstitial Lung Disease Program at Tufts Medical Center in Boston.

Read Bio
Dr. Raphael Bueno

Raphael Bueno

Pleural Specialist | Thoracic Surgery

Expertise:
Pleurectomy and Decortication Extrapleural Pneumonectomy
Brigham and Women’s Hospital • Boston, Massachusetts
View Profile
Expertise:
Pleurectomy and Decortication Extrapleural Pneumonectomy
Brigham and Women’s Hospital
Boston, Massachusetts
View Profile

Dr. Raphael Bueno is the Division of Thoracic Surgery chief at Brigham and Women’s Hospital in Boston and director of the renowned International Mesothelioma Program.

Read Bio
Dr. Henning A. Gaissert

Henning A. Gaissert

Pleural Specialist | Thoracic Surgery

Expertise:
Multimodal Therapy Thoracic Malignancies
Massachusetts General Hospital • Boston, Massachusetts
View Profile
Expertise:
Multimodal Therapy Thoracic Malignancies
Massachusetts General Hospital
Boston, Massachusetts
View Profile

Dr. Henning Gaissert is chief of thoracic surgery at Newton-Wellesley Hospital and a cardiothoracic surgeon at nearby Massachusetts General Hospital. He handles his dual role with distinction.

Read Bio
Dr. Martin D. Goodman

Martin D. Goodman

Peritoneal Specialist | Surgical Oncology

Expertise:
Cytoreductive Surgery HIPEC
Tufts Medical Center • Boston, Massachusetts
View Profile
Expertise:
Cytoreductive Surgery HIPEC
Tufts Medical Center
Boston, Massachusetts
View Profile

Surgical oncologist Dr. Martin D. Goodman has been treating patients with peritoneal mesothelioma for more than a decade at the Tufts Medical Center in Boston.

Read Bio
Dr. Pasi A. Janne

Pasi A. Janne

Pleural Specialist | Thoracic Oncology

Expertise:
Immunotherapy Heated Chemotherapy
Dana-Farber Cancer Institute • Boston, Massachusetts
View Profile
Expertise:
Immunotherapy Heated Chemotherapy
Dana-Farber Cancer Institute
Boston, Massachusetts
View Profile

Dr. Pasi A. Janne is scientific co-director of the Belfer Institute for Applied Cancer Science and a practicing oncologist and researcher at the Lowe Center for Thoracic Oncology.

Read Bio
Dr. Hassan A. Khalil

Hassan A. Khalil

Pleural Specialist | Thoracic Oncology

Expertise:
Thoracic Surgery Robotic Surgery
Brigham and Women’s Hospital • Boston, Massachusetts
View Profile
Expertise:
Thoracic Surgery Robotic Surgery
Brigham and Women’s Hospital
Boston, Massachusetts
View Profile

Thoracic surgeon Dr. Hassan Khalil treats patients with lung cancer and mesothelioma at Brigham and Women’s Hospital in Boston.

Read Bio
Dr. Scott J. Swanson

Scott J. Swanson

Pleural Specialist | Thoracic Surgery

Expertise:
Minimally Invasive Surgery Video-Assisted Surgery
Brigham and Women’s Hospital • Boston, Massachusetts
View Profile
Expertise:
Minimally Invasive Surgery Video-Assisted Surgery
Brigham and Women’s Hospital
Boston, Massachusetts
View Profile

Dr. Scott Swanson is the well-respected director of the minimally invasive thoracic surgery program at Brigham and Women’s Hospital in Boston.

Read Bio
Find a Specialist Near You

Begin your search for a doctor in your area.

Searching…

Get started by selecting location, type, specialty or language.

Clinical Trials in Massachusetts

Massachusetts mesothelioma cancer centers conduct extensive research to improve mesothelioma care, offering those facing the cancer access to clinical trials that test new therapies. Hospitals like Tufts Medical Center in Boston enroll patients in clinical trials for innovative treatments, such as immunotherapy medications and CAR T-cell therapy. To learn if you’re eligible for clinical trials, speak with your mesothelioma doctor in Massachusetts or our experienced Patient Advocates.

NCT05730816

MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI

In this research study, investigators will test whether prophylactic high-dose IV Mg administration attenuates the risk of AKI in patients with malignant mesothelioma receiving intraoperative chemotherapy (HIOC) with cisplatin compared to placebo .

Locations

  • Massachusetts (1)

    • Brigham and Women's Hospital — Boston

NCT02012699

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.

Locations

  • Colorado (1)

    • Advent Health — Greenwood Village

  • Connecticut (1)

    • Hartford HealthCare Cancer Institute at Manchester Medical Hospital — Manchester

  • Florida (5)

    • Florida Hospital Memorial Medical Center — Daytona Beach
    • Florida Hospital DeLand — DeLand
    • Florida Hospital FISH — Orange City
    • Florida Hospital Flagler — Palm Coast
    • Tallahassee Memorial Hospital — Tallahassee

  • Illinois (2)

    • Rush-Copley Cancer Care Center — Aurora
    • Rush-Copley Healthcare Center — Yorkville

  • Indiana (1)

    • Parkview Research Center — Fort Wayne

  • Iowa (2)

    • Methodist Jennie Edmundson Hospital — Council Bluffs
    • Covenant Medical Center, Inc — Waterloo

  • Kansas (1)

    • Saint Luke's Cancer Instititute – South — Overland Park

  • Maryland (2)

    • Northwest Hospital — Randallstown
    • William E. Kahlert Regional Cancer Center — Westminster

  • Massachusetts (1)

    • Holyoke Medical Center — Holyoke

  • Minnesota (5)

    • Riverwood Healthcare Center — Aitkin
    • Essentia Health-St. Joseph's Medical Center — Brainerd
    • Essentia Health – Duluth Clinic — Duluth
    • St. Luke's Hospital of Duluth — Duluth
    • Lake Region Healthcare — Fergus Falls

  • Missouri (6)

    • Saint Luke's Cancer Institute, East — Kansas City
    • Saint Luke's Cancer Institute — Kansas City
    • Saint Luke's Cancer Institute, Kansas City North — Kansas City
    • Saint Luke's Cancer Institute, Liberty — Liberty
    • North Kansas City Hospital — North Kansas City
    • Heartland Regional Medical Center dba Mosaic Life Care — Saint Joseph

  • Montana (1)

    • Bozeman Health Deaconess Hospital — Bozeman

  • Nebraska (6)

    • Mary Lanning Healthcare, Morrison Cancer Center — Hastings
    • Faith Regional Health Services, Carson Cancer Center — Norfolk
    • Great Plains Regional Medical Center — North Platte
    • Methodist Estabrook Cancer Center — Omaha
    • Nebraska Methodist Health System — Omaha
    • University of Nebraska Medical Center — Omaha

  • New York (2)

    • C.R. Wood Cancer Center, Glens Falls Hospital — Glens Falls
    • Faxton St. Luke's Healthcare, Mohawk Valley — Utica

  • North Carolina (1)

    • Cape Fear Valley Health System — Fayetteville

  • North Dakota (2)

    • Essentia Health — Fargo
    • Trinity Hospital Cancer Care Center — Minot

  • Ohio (2)

    • Aultman Alliance Community Hospital — Alliance
    • Aultman Hospital — Canton

  • Wisconsin (1)

    • Bellin Memorial Hospital — Green Bay

NCT04115254

Stereotactic Magnetic Resonance Guided Radiation Therapy

This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer. * The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer. * Phase 2 will evaluate efficacy of SMART with specific reference to tumor control and improvement in patient reported outcome measures

Locations

  • Massachusetts (2)

    • Brigham & Women's Hospital — Boston
    • Dana Farber Cancer Institute — Boston

NCT06538376

Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU

Dynamic digital radiography (DDR) is a new advanced version of chest radiography that captures dynamic images at a rate of 15 frames per second. It is coupled with an analytical software that allows it to provide more advanced measures of lung motion, ventilation, and perfusion compared to traditional chest radiography. While implementation of DDR fixed machines are beginning elsewhere in the US, this trial involves the first applications of an FDA-approved portable DDR machine, for use at the bedside in the ICU. The goal of this clinical trial is to determine the feasibility and safety of portable DDR technology in the ICU, as well as to evaluate the improved clinical diagnostic value of the portable DDR system over current standards of care. Participants will receive one to three sets of DDR images, which will then be compared to their clinical gold standard exams (such as chest x-rays, CTs, or VQ scans) to assess and improve the precision and accuracy of measurements such as diaphragmatic motion, lung movement, and perfusion.

Locations

  • Massachusetts (1)

    • Brigham and Women's Hospital — Boston

NCT03683680

Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers

This research study is evaluating a new method for determining stage and prognosis of individuals with malignant pleural mesothelioma.

Locations

  • Massachusetts (1)

    • Brigham and Women's Hospital — Boston

NCT05579366

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

Locations

  • Arizona (2)

    • USOR HonorHealth — Phoenix
    • USOR Arizona Oncology Associates — Tucson

  • California (4)

    • University of California Los Angeles Medical Center — Los Angeles
    • University of California, San Diego; Moores Cancer Center — San Diego
    • USOR Sansum Clinic — Santa Barbara
    • Providence Medical Foundation — Santa Rosa

  • Florida (3)

    • USOR Florida Cancer Specialists South — Fort Myers
    • USOR Florida Cancer Specialists North — St. Petersburg
    • USOR Florida Cancer Specialists East — West Palm Beach

  • Georgia (1)

    • Augusta University Georgia Cancer Center — Augusta

  • Kansas (1)

    • University of Kansas Medical Center (KUMC) — Westwood

  • Maryland (1)

    • USOR Maryland Oncology Hematology — Rockville

  • Massachusetts (2)

    • Massachusetts General Hospital — Boston
    • Dana Farber Cancer Institute — Boston

  • Michigan (2)

    • Karmanos Cancer Institute — Detroit
    • START Midwest — Grand Rapids

  • Minnesota (1)

    • USOR Minnesota Oncology Hematology — Maplewood

  • New Jersey (1)

    • MD Anderson Cancer Center at Cooper- Two Cooper Plaza — Camden

  • Ohio (1)

    • Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute — Columbus

  • Oklahoma (1)

    • University of Oklahoma – Health Sciences Center — Oklahoma City

  • Oregon (2)

    • USOR Oncology Associates of Oregon, P.C. — Eugene
    • Compass Oncology – Rose Quarter — Portland

  • Pennsylvania (2)

    • USOR Alliance Cancer Specialist — Doylestown
    • Allegheny Health Network — Pittsburgh

  • Rhode Island (1)

    • Women and Infants Hospital of Rhode Island — Providence

  • Tennessee (2)

    • Sarah Cannon Research Institute at Tennessee Oncology — Nashville
    • Tennessee Oncology — Nashville

  • Texas (6)

    • USOR Texas Oncology — Abilene
    • Texas Oncology – Central / South Texas — Austin
    • Mary Crowley Cancer Research — Dallas
    • USOR Texas Oncology — Fort Worth
    • Texas Oncology – Northeast TX — Tyler
    • USOR Texas Oncology Gulf Coast — Woodland

  • Utah (1)

    • START Mountain Region — West Valley City

  • Virginia (2)

    • USOR Virginia Cancer Specialists — Fairfax
    • USOR Virginia Oncology Associates — Norfolk

  • Washington (1)

    • Swedish Cancer Institute — Seattle

NCT04104776

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid tumors and lymphomas.

Locations

  • Georgia (1)

    • Winship Cancer Institute of Emory University — Atlanta

  • Illinois (1)

    • University of Chicago Medical Center — Chicago

  • Massachusetts (1)

    • Massachusetts General Hospital — Boston

  • Pennsylvania (1)

    • Abramson Cancer Center of the University of Pennsylvania — Philadelphia

  • Virginia (1)

    • University of Virginia Health System — Charlottesville

  • Washington (2)

    • Swedish Cancer Institute — Seattle
    • Fred Hutchinson Cancer Center — Seattle

NCT05732831

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.

Locations

  • California (1)

    • Stanford University — Palo Alto

  • Colorado (1)

    • Grand Valley Oncology — Grand Junction

  • Florida (1)

    • Sylvester Comprehensive Cancer Center — Miami

  • Illinois (3)

    • University Chicago Medicine — Chicago
    • Carle Cancer Center — Urbana
    • Midwestern Regional Medical Center, City of Hope Chicago — Zion

  • Massachusetts (2)

    • Massachusetts General Hospital — Boston
    • Dana Farber Cancer Institute — Boston

  • Michigan (1)

    • Henry Ford Cancer Center — Detroit

  • New York (1)

    • New York University Langone Health — New York

  • Tennessee (1)

    • Sarah Cannon Tennessee Oncology — Nashville

  • Texas (1)

    • The University of Texas MD Anderson Cancer Center — Houston

  • Utah (1)

    • Huntsman Cancer Institute, University of Utah — Salt Lake City

  • Virginia (1)

    • Next Oncology Virginia — Fairfax

NCT04665206

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.

Locations

  • California (1)

    • UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco

  • Illinois (1)

    • University of Chicago Medical Center — Chicago

  • Massachusetts (2)

    • Massachusetts General Hospital — Boston
    • Dana-Farber Cancer Institute — Boston

  • Minnesota (1)

    • M Health Fairview University of Minnesota Medical Center — Minneapolis

  • New York (1)

    • Memorial Sloan Kettering Cancer Center — New York

  • Texas (2)

    • MD Anderson Cancer Center — Houston
    • NEXT Oncology — San Antonio

  • Virginia (1)

    • Virginia Cancer Specialists, PC — Arlington

NCT05245500

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

Locations

  • Arizona (1)

    • Mayo Clinic — Phoenix

  • Colorado (1)

    • Rocky Mountain Cancer Centers, LLP – Oncology — Lone Tree

  • Florida (2)

    • Mayo Clinic — Jacksonville
    • Sarah Cannon Research Institute at Florida Cancer Specialists — Orlando

  • Massachusetts (1)

    • Dana-Farber Cancer Institute — Brookline

  • Michigan (2)

    • The Cancer & Hematology Centers — Grand Rapids
    • Cancer and Hematology Centers of Western Michigan — Norton Shores

  • Minnesota (1)

    • Mayo Clinic — Rochester

  • New Jersey (1)

    • Rutgers Cancer Institute of New Jersey — New Brunswick

  • New York (4)

    • Perlmutter Cancer Center at NYU Langone Hospital Long Island — Mineola
    • David H Koch, Memorial Sloan Kettering Cancer Center — New York
    • New york cancer and blood specialists – Oncology — Port Jefferson Station
    • New york cancer and blood specialists – Oncology — Port Jefferson Station

  • North Carolina (2)

    • University of North Carolina – Gastroenterology and Hepatology — Chapel Hill
    • University of North Carolina — Chapel Hill

  • Tennessee (1)

    • Vanderbilt – Ingram Cancer Center — Nashville

  • Texas (5)

    • Ut Southwestern — Dallas
    • Texas Oncology – DFW — Fort Worth
    • MDACC — Houston
    • South Texas Accelerated Research Therapeutics — San Antonio
    • Texas Oncology, P.A. – Oncology — Tyler

  • Virginia (1)

    • Virginia Cancer Specialists, PC — Fairfax

Financial Aid in Massachusetts

People with mesothelioma in Massachusetts can apply for many types of financial aid. State and national programs like Health Safety Net can help with medical care costs, such as equipment and co-pays. Other nonprofits cover emergency household needs like rent and groceries, such as Marisa’s Mission in Norfolk County and Cancer1Source in Worcester County.

Economic Help for Mesothelioma Patients

  • Cancer1Source: Based in Princeton, Cancer1Source offers financial aid to people with cancer or who are seeking genetic testing or counseling. If you’re facing financial hardship and live in Massachusetts or are receiving mesothelioma treatment at one of the state’s cancer centers, you may be eligible for one of the nonprofit’s programs. Depending on availability, funds of up to $150 per year can help with wigs or hairpieces, medication costs, and travel or lodging expenses for treatment, among other needs.
  • Cancer Support Fund of Central Mass: People receiving mesothelioma treatment at Heywood Healthcare Hospital in Athol or Gardner, or the Simonds-Sinon Regional Cancer Center in Fitchburg may qualify for financial aid from this nonprofit. Cancer Support Fund can cover medical and non-medical needs related to mesothelioma treatment in Massachusetts, including co-pays, medical equipment costs, prescriptions, massage therapy, groceries and mortgage payments.
  • Health Safety Net: This state program can cover medical bills and prescription costs for Massachusetts residents who meet certain income standards and are uninsured or underinsured. Health Safety Net isn’t exclusive to people with cancer, so caregivers or other loved ones may benefit from this program if they meet requirements, too. You may only use HSN at community health centers or acute care hospitals, and it covers facility charges at those locations.
  • Joe Andruzzi Foundation: Serving people with cancer throughout New England, the Joe Andruzzi Foundation supports those undergoing treatment. Grant amounts vary by program. For instance, grocery assistance can be between $150 and $300 depending on family size, and one-time grants of up to $4000 are available for qualifying extraordinary needs. Generally, funds can cover expenses like rent or mortgage payments, car insurance, utilities and more. Transportation is also available.
  • Patient Financial Assistance programs: Several cancer centers in Boston offer financial assistance to low-income families or individuals struggling to cover the costs of mesothelioma treatment in Massachusetts.

U.S. veterans with mesothelioma and their families can contact our Veterans Department for help applying for disability compensation or survivor benefits. Our experienced team is happy to help veterans with mesothelioma navigate any steps that seem complicated. We also support Massachusetts families with Patient Advocate services, answering questions, explaining available options and helping families locate financial aid resources that fit.

Cancer Resources in Massachusetts

Cancer nonprofits like Cancer Support Community coordinate support networks and wellness programs for people living with mesothelioma and their caregivers in Massachusetts. These programs focus on providing emotional, mental, spiritual and physical care during diagnosis, treatment and recovery. Spouses and family members can also find bereavement support networks and professional counseling.

Massachusetts Cancer Support Programs

  • American Cancer Society – Massachusetts: The Massachusetts ACS Resource Center helps people with mesothelioma find emotional support groups, transportation and lodging options during treatment, along with free wigs and hats.
  • Cam Neely Foundation: Based in Boston, the Cam Neely Foundation provides lodging for people receiving treatment at the Tufts Medical Center, along with their families. There is no minimum or maximum lodging length for stays at The Neely House, and the nonprofit has helped more than 6,500 families from Massachusetts and other states.
  • Cancer Support Community Massachusetts: People facing mesothelioma throughout Massachusetts can access educational resources and an online community of people living with mesothelioma, caregivers and family members who offer comfort and support. CSC Massachusetts also provides a cancer support helpline with licensed oncologists.
  • Dana-Farber Cancer Institute: People in treatment for mesothelioma at this cancer center can benefit from a wide range of support resources, including meal planning and licensed nutritionist services, food baskets and psychotherapy support sessions. At the nearby Leonard P. Zakim Center for Integrative Therapies and Healthy Living, they can participate in free wellness activities taught by certified professionals, including massage and acupuncture, exercise and gentle movement classes, stress relief programs and creative arts activities.
  • Massachusetts General Hospital: The Maxwell V. Blum Cancer Resource Room at Mass General provides a comfortable, homey space for people to talk about their questions and concerns with clinicians. The hospital also provides access to integrative therapies such as acupuncture, music therapy and yoga through the Katherine A. Gallagher Integrative Therapies Program, supporting the well-being of people with cancer and their families during cancer treatment.

In partnership with the Massachusetts Emergency Management Agency, United Way nonprofits throughout the state offer free helpline and information services. Simply dial 211 to learn more about local and regional programs for utility assistance, transportation, meal delivery services, food banks and mental health support.

What Survivors Say About Their Mesothelioma Treatment in Massachusetts

People with mesothelioma who have received mesothelioma treatment in Massachusetts have shared their advice and experiences with our Patient Advocate team. The experiences of local mesothelioma survivors reflect the innovative and advanced programs across the state.

Survivor Experience

“My faith and my wife helped me the most during my recovery,” Joey said. “Our faith pretty much helps us through everything. Holding onto my faith helped me move through everything further and quicker.”

– Joey B. , Pleural Mesothelioma Survivor
Verified Asbestos.com Survivor